Biotech Values

[dewophile]

3) Other indications that they plan to pursue are inflammatory anemias (e.g. Lupus Nephritis, Inflammatory Bowel Disease, Rheumatoid Arthritis, Myelodisplastic syndrome)
I wonder why they aren't already running trials in these specific additional indications

I would guess it is because the large safety trials are gating for approval, and if successful running efficacy trials and getting sNDAs approved would be fast and easy, so more cost conscience to do it sequentially

FWIW, I actually had in my notes that last meeting was 4/26, not 4/22. Will double-check that. Important because I may time my next add until after this next planned meeting. I'm assuming if there was a negative issue, we would likely hear about that in a PR the following morning or after the close

on the earnings call march 26 the company was talking about a DSMB review that had taken place recently - so i assume the april meeting was the face to face, and the quarterly data review happens some time prior - correct me if i am wrong (so this would put the next data review end of the month and meeting w company in october since this is every 6 months or so per the company